PRA Health Sciences Inc. was growing in short interest into August. A rise of 10.6% from the August 15th total of 846,400 shares as of August 31st, there was short interest totaling 936,500 shares. Based for an average volume that is daily of shares, the days-to-cover ratio happens to be 3.0 days. Currently, 1.5% of the shares for the ongoing company are offered quick.
NASDAQ PRAH traded down $1.92 during trading on, reaching $101.19 Friday. 3,642 shares of the company traded fingers, compared to its volume that is average of. The business includes a debt-to-equity ratio of 1.08, a ratio that is quick of and a current ratio of 0.98. The stock’s 50 day average that is moving is $103.82 and its two-hundred day moving average price is $95.12. An industry is had by the company limit of $6.60 billion, a price-to-earnings ratio of 31.63, a P/E/G ratio of 2.31 and a beta of 1.02. PRA Health Sciences has a low that is 1-year of58.67 and a 1-year high of $113.32.
PRA Health Sciences (NASDAQ:PRAH) last released its earnings that are quarterly on Thursday, August 6th. The research that is medical reported $0.69 profits per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.05. PRA Health Sciences had a return on equity of 25.01% and a margin that is web of%. The company had revenue of $729.89 million for the quarter, compared towards the consensus estimate of $716.12 million. The business earned $1.22 earnings per share during the same period in the last year. The business’s quarterly revenue ended up being down 4.4percent on a foundation that is year-over-year. Equities research analysts expect that PRA Health Sciences will post 3.71 EPS for the current year that is fiscal.
A number of brokerages have issued reports on PRAH. UBS Group increased their price target on PRA Health Sciences from $105.00 to $111.00 and gave the company a “neutral” rating in a research note on, August 10th Monday. BidaskClub raised PRA Health Sciences from a “sell” rating to a “hold” rating in a research note on, September 11th Friday. Credit Suisse Group increased their price target on PRA Health Sciences from $113.00 to $116.00 and provided the business an “outperform” rating in a research note on, August 7th Friday. BofA Securities lowered PRA Health Sciences from a “buy” rating to an “underperform” rating and decreased their price target for the company from $110.00 to $100.00 in a research note on, August 10th Monday. Finally, Bank of America lowered PRA Health Sciences from a “neutral” rating to an “underperform” rating and set a $100.00 price objective for the company. in a research note on, August 10th Monday. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy score to the company’s stock. The company presently posseses an average rating of “Hold” as well as an target that is average of $105.23. PRA Health Sciences Inc. was growing in short interest into August.